Last updated on October 2018

A Six Week Efficacy Safety and Tolerability Study of V565 in Crohn's Disease


Brief description of study

The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease.

Detailed Study Description

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of two treatment arms: either V565 or placebo using a 2:1 active:placebo ratio for a treatment period of 6 weeks.

Subjects will be treated with study drug as an add-on to any permitted stable medications already being taken for CD.

Clinical Study Identifier: NCT02976129

Find a site near you

Start Over

Sarkis Clinical Trials

Gainesville, FL United States
  Connect »

Galiz Research, LLC

Miami Springs, FL United States
  Connect »

Via Christi Research

Wichita, KS United States
  Connect »

Clinical Trials of America

Mount Airy, NC United States
  Connect »

Global Medical Research

DeSoto, TX United States
  Connect »

CI City Hospital #1

Zaporizhzhia, Ukraine
  Connect »

St Thomas' Hospital

London, United Kingdom
  Connect »

West Central Gastroenterology

Clearwater, FL United States
  Connect »

Northwestern University

Evanston, IL United States
  Connect »

EUGASTRO GmbH

Leipzig, Germany
  Connect »

ETZ Elisabeth

Tilburg, Netherlands
  Connect »

Praxis fuer Magen

Heidelberg, Germany
  Connect »

DRC Gyogyszervizsgalo

Balatonfüred, Hungary
  Connect »